Will 2018 Be Johnson & Johnson's Best Year Yet?
There are still several weeks left in the year, but Johnson & Johnson (NYSE: JNJ) appears to be on course to generate its second-highest stock performance over the last decade in 2017. A couple of major acquisitions helped the healthcare giant boost revenue to an all-time high in the third quarter.
As the new year approaches, though, investors are more focused on the future than the past. Will 2018 be Johnson & Johnson's best year yet? Probably yes. And probably no.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Aktie
225,10 €
-0,90 %
Uneingeschränkte Unterstützung für Johnson & Johnson, ausschließlich Buy-Einschätzungen.
Ein Kursziel von 228 € für Johnson & Johnson impliziert ein leicht positives Wachstum gegenüber dem aktuellen Kurs von 225.1 €.
